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The synthesis of a novel series of Mannich bases of 5-methyl-3-substituted piperazinomethyl-2benzoxazolinones is described. The structures attributed to compounds 3c, 3d and 3f-3n were elucidated using IR and 1 H NMR spectroscopic techniques as well as elemental analysis. The compounds were
examined for their in vivo anti-inﬂammatory and analgesic activities in 2 diﬀerent bioassays, namely,
carrageenan-induced hind paw edema and p-benzoquinone-induced abdominal constriction tests in mice,
respectively. In addition, the ulcerogenic eﬀects of the compounds were determined. Among the derivatives tested the most promising results were obtained for the compounds bearing electron-withdrawing
substituents (F, Cl, COCH3 ) in the para position of the phenyl nucleus on the piperazine ring at the 3
position of benzoxazolinone moiety (3a, 3c, 3i). The analgesic activities of all compounds are higher
than their anti-inﬂammatory activities and therefore these high analgesic activities indicated that the
compounds could a show central eﬀect.
Key Words: 5-Methyl-2-Benzoxazolinone, Mannich Reaction, Analgesic, Anti-inﬂammatory Activities.

Introduction
Non-steroidal anti-inﬂammatory drugs (NSAIDs) are widely used. Despite their large number, none is very
eﬀective therapeutically, and almost all have several undesired, often serious, side eﬀects1 and so longterm
administration is not advisable. Thus the need for new anti-inﬂammatory drugs is obvious. Therefore,
there has been renewed interest in anti-inﬂammatory agents endowed with either more selective mechanisms
(COX-1 vs. COX-2 inhibition)2 or novel modes of action. One of these novel action modes is inhibition
of inducible nitric oxide synthase (NOS), which contributes to acute and chronic inﬂammation3−5. In this
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context, it has been shown that some benzoxazolinone derivatives, especially 5-methyl analogs, as shown
in the general structure (Figure), inhibit NOS and they constitute a novel class of non-aminoacid NOS
inhibitors6 .
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Figure

Currently there is considerable therapeutic interest in novel drugs containing 1-arylpiperazinyl moieties, in particular, due to their eﬀects on the central nervous system7−10 . At the same time, the introduction of (4-aryl-piperazin-1-yl)alkyl moieties on various heterocyclic nuclei such as benzoxazolinones11−12 ,
oxazolopyridine13−14, pyridazine15−16 and pyrazolo-triazine17 led to favorable antinociceptive compounds.
As part of the continuing eﬀorts of our laboratory to develop new analgesics, we initiated a research program
based on the synthesis of benzoxazolinone derivatives substituted by arylpiperazinylalkyl chains18−19 at the
C-3 position. In this study, the eﬀect caused by the introduction of arylpiperazinyl moieties at the C-3
position of 5-methyl-2-benzoxazolinones was evaluated.

Experimental
Chemistry
All chemicals were purchased from Aldrich Chemical Co. Melting points were detected with a Thomas
Hoover capillary melting point apparatus and are uncorrected. The IR spectra (KBr) were recorded on a
Bruker Vector 22 FT-IR spectrophotometer. The 1 H NMR spectra were obtained by Bruker AC 80 MHz
and Bruker 400 MHz using CDCl3 as solvent and tetramethylsilane as internal standard. Splitting patterns
were designated as follows: s: singlet, d: doublet, t: triplet, q: quartet, and m: multiplet. All chemical
shift values were recorded as δ (ppm). Mass spectra were recorded on a Jeol AX505W mass spectrometer
with electron ionization (EI). The purity of the compounds was determined by thin layer chromatography
(Merck, silicagel, HF254−366, Type 60, 0.25 mm). The elemental analyses were performed on a Leco CHNS
932 analyzer at the Scientiﬁc and Technical Research Council of Turkey (TÜBİTAK), Instrumental Analysis
Laboratory in Ankara.
5-Methyl-2-benzoxazolinone
A modiﬁcation of the procedure described by Bywater20 et al. was followed using 0.1 mol 4-methyl-2aminophenol and 0.12 mol urea. The mixture was fused at 145-150 ◦ C for 4 h in a preheated oil bath. The
residue was recrystallized from water. [C8 H7 NO2 : Yield: 59.7% , mp 131-2 ◦ C, IR: ν: 1791 cm−1 (C=O),
1

H-NMR: 2.4 (3H; s; 5-CH3 ), 6.9-7.3 (3H; m; Arom-H.), 9.2 (1H; s; N-H).

5-Methyl-3-substituted piperazinomethyl-2-benzoxazolinones
The title compounds were prepared by vigorously stirring a solution of 0.1 mol of the substituted piperazine
derivative and 0.1 mol of 5-methyl-2-benzoxazolinone in methanol. Then 0.12 mol of formaline (37% w/v)
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was added and the mixture reﬂuxed in a water bath for 1 h. The reaction mixture was poured onto crushed
ice and the resulting precipitate was ﬁltered, dried and puriﬁed by crystallization with appropriate solvents
21,22

.

Pharmacology
Male Swiss albino mice (20-25 g) were purchased from the animal breeding laboratories of the Reﬁk Saydam
Hıfzısıhha Institute (Ankara, Turkey). The animals were left for 2 days for acclimatization to animal room
conditions and were maintained on a standard pellet diet and water ad libitum. The feeding was stopped
on the day before the experiment, but they were allowed free access to water. Test samples and reference
compounds were suspended in 0.5% carboxymethyl cellulose and administered to each mouse using a gastric
gavage needle. The control group animals, however, received the same volume of dosing vehicle. In the
pharmacological studies, the animals were ﬁrst administered a 100 mg/kg (body weight) dose of the test
drugs.

p-Benzoquinone-induced abdominal constriction test in mice23
One hour after the oral administration of test samples, the mice were intraperitoneally injected with 0.1
mL/10 g body weight of 2.5% (v/v) p-benzoquinone (PBQ; Merck) solution in distilled water. Control
animals received an appropriate volume of dosing vehicle.

The mice were then kept individually for

observation and the total number of abdominal contractions (writhing movements) was counted for the
subsequent 15 min, starting 5 min after the PBQ injection. The data represent averages of the total numbers
of writhes observed. The antinociceptive activity was expressed as percentage change from writhing controls.
Aspirin (ASA) was used as a reference.

Carrageenan-induced paw edema model24
For the determination of the eﬀects on carrageenan-induced paw edema the modiﬁed method of Kasahara et
al. was employed. One hour after the oral administration of either the test sample or the dosing vehicle, each
mouse was injected with a freshly prepared (0.5 mg/25 µL) suspension of carrageenan (Sigma, St. Louis,
Missouri, USA) in physiological saline (154 mM NaCl) into the subplantar tissue of the right hind paw. As
the control, 25 µL of saline solution was injected into the left hind paw. Paw edema was measured every
90 min for 6 h after the induction of inﬂammation. The diﬀerence in footpad thickness between the right
and left foot was measured with a pair of dial thickness gauge callipers (Ozaki Co., Tokyo, Japan). Mean
values of treated groups were compared with mean values of the control group and analyzed statistically22 .
Indomethacine (INDO) was used as a reference compound.

Gastric ulceration study
All the animals were sacriﬁced immediately after the last measurement under ether anesthesia and their
stomachs were removed. The stomachs were examined for lesions under a dissecting microscope. Stomachs
exhibiting one or more ulcers were considered positive.
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Statistical analysis of data
Data obtained from animal experiments were expressed as mean standard error (±SEM). Statistical diﬀerences between the treatment and control groups were tested by two-tailed Student’s t-test. P < 0.05 was
considered signiﬁcant.

Results and Discussion
A series of novel derivatives of 5-methyl-3-substituted piperazinomethyl-2-benzoxazolinones was synthesized
(Scheme) in an attempt to ﬁnd improved analgesic-anti-inﬂammatory agents. One of the most interesting
characteristics of these novel compounds is their basic nature, which diﬀerentiates them from the classical, acidic nonsteroidal antiinﬂammatory agents. It was of interest, therefore, to study the analgesicantiinﬂamatory properties of these novel compounds.
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The synthesis pathway, leading to the title compounds, is given in Scheme. 5-Methyl-2-benzoxazolinone, starting material 2, was synthesized according to the literature method using 5-methyl-2-hydroxyaniline
and urea20 . The ﬁnal compounds 3a-3n were prepared from 5-methyl-2-benzoxazolinone, arylpiperazine
derivatives and formaldehyde according to the Mannich reaction in 60-85% yield. The structure attributed
to compounds 3c, 3d and 3f-3n was supported by the results of elemental analysis as well as by the IR
and 1 H-NMR spectra. Melting points, yields % , formulae and spectral characterizations of the synthesized
compounds are given in Table 1. All spectral data are in accordance with the assumed structures. In the IR
spectra of the compounds, no absorption bands were detected at 3100-3400 cm−1 , indicating the absence of
an NH group, which is evidence for the additional reaction. The lactam C=O stretching band was seen at
about 1780 cm−1 and aliphatic stretching bands belonging to a piperazine ring appeared at about 2900 cm−1 .
In the 1 H-NMR spectra of the compounds, the CH2 protons of compounds 3c, 3d and 3f-3n were seen at
about 4.6-4.8 ppm as a singlet. The H2 and H6 protons of the piperazine ring were seen at about 2.3-3.0 ppm
and the H3 and H5 protons were observed at 2.7-3.8 ppm. 5-Methyl protons bound to 2-benzoxazolinone
appeared at approximately 2.2-2.4 ppm. In the EI-MS spectra of 3f, 3k and 3l, molecular ion M+ peaks,
which appeared at diﬀerent intensities conﬁrmed the molecular weights of the examined compounds. In the
spectra of compounds 3f and 3k the base peak resulted from loss of an amine moiety plus CH2 group while
in the spectra of compound 3l the lost group was the base peak.
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R

4-Fluorophenyl

2-Fluorophenyl

4-Chlorophenyl

3-Chlorophenyl

2-Chlorophenyl

2-Methoxyphenyl

3-Methoxyphenyl

2,3-Dimethylphenyl

Comp.

3a*

3b*

3c

3d

3e*

3f

3g

3h

C19 H20 FN3 O2
(341,38)
C19 H20 FN3 O2
(341,38)
C19 H20 ClN3 O2
(357,83)
Calcd: C:63.77; H:5.63; N:11.74
Found: C:63.79; H:5.83; N:11.61
C19 H20 ClN3 O2
(357.83)
Calcd: C:63.77; H:5.63; N:11.74
Found: C:63.62; H:5.37; N:11.71
C19 H20 ClN3 O2
(357,83)
C20 H23 N3 O3
(353,42)
Calcd: C:67.97; H:6.56; N:11.89
Found: C:67.42; H:5.32; N:11.85
C20 H23 N3 O3
(353,42)
Calcd: C:67.97; H:6.56; N:11.89
Found: C:67.67; H:6.17; N:11.56
C21 H25 N3 O2
(351.42)
Calcd: C:71.7; H:7.17; N:11.96
Found: C:71.67; H:7.23; N:11.82

Formula

CH 3
O

80

79

69

74

66

60

81

167-681
144-451

168-692

146-72

159-602

156-581

108-093

141-23

N

Yield
%
82

M.p.

O

N CH2 N

1764a

1763a

1778a

1754a

1769a
1769a

IR
(KBr)
(cm−1 )

R

Ref. 21

1
H-NMR
(CHCl3 -d1 ) δ (ppm)
Ref. 21

2,4 (3H; s; -CH3 ); 2,9-2,7 (4H; s; pip. H2 ,
H6 ); 3,2-3,0 (4H; s; pip. H3 , H5 ); 3,8 (3H;
s; -OCH3 ), 4,7 (2H; s; -CH2 -); 7,3-6,7
(7H; m; Arom-H.)
2,2 (3H; s; -CH3 ); 3,4-3,0 (4H; d; pip. H3 ,
2,2 (3H; s; -CH3 ); 3,4-3,0 (4H; d; pip. H3 ,
s; -OCH3 ); 4,8 (2H; s; -CH2 -); 7,4-6,2
(7H; m; Arom-H.).
2.1 (3H; s; CH3 (o)-Ph-N), 2.2 (3H; s;
CH3 (m)-Ph-N), 2.3 (3H; s; 5-CH3 ), 2.9
(8H; s; pip. H2 , H3 , H5 , H6 ), 4.6 (2H; s;
N-CH2 -N-), 6.8-7.3 (6H; m; Arom-H.)

2.3 (3H; s; 5-CH3 ), 2.8 (4H; t; pip. H2 ,
H6 ), 3.2 (4H; t; pip. H3 , H5 ), 3.4 (2H; s; NCH2 -C), 4.60 (2H; s; N-CH2 -N-), 6.6-7.4
(7H; m; Arom-H.)
Ref. 22

2,35 (3H; s; -CH3 ); 2,9-2,7 (4H; t; pip. H2 ,
H6 ); 3,2-2,9 (4H; t; pip. H3 , H5 ); 4,6 (2H;
s; -CH2 -); 7,2-6,6 (7H; m; Arom-H.).

Table 1. Characterization and spectral data of compounds 3a-3n.
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4-Acetylphenyl

2-Pyrimidinyl

3Triﬂuoromethylphenyl

2-Pyridyl

Benzyl

Piperonyl

3i

3j

3k

3l

3m

3n
Calcd:
Found:

Calcd:
Found:

Calcd:
Found:

Calcd:
Found:

Calcd:
Found:

Calcd:
Found:

C21 H23 N3 O3
(365.43)
C:69.02; H:6.34; N:11.50
C:69.43; H:5.87; N:11.37
C17 H19 N5 O2
(339,39)
C:62.75; H:5.89; N:21.52
C:62.92; H:5.49; N:21.21
C20 H20 F3 N3 O2
(391.39)
C:61.38; H:5.15; N:10.74
C:61.63; H:4.85; N:10.52
C18 H20 N4 O2
(324.38)
C:66.65; H:6.21; N:17.17
C:66.17; H:6.32; N:17.20
C20 H23 N3 O2
(337.42)
C:71.19; H:6.87; N:12.45
C:71.36; H:6.62; N:12.36
C21 H23 N3 O4
(381.43)
C:66.13; H:6.08; N:11.02
C:66.07; H:6.29; N:11.13

Formula

a

Acetone-water, 2 Methanol, 3 Ethanol, 4 Ethanol-water
lactam
*Compounds 3a,3b,3e were prepared previously [21,22]

1

R

Comp.

CH 3
O

104-54

103-54
103-54

117-81

159-604

170-11

156-81

M.p.

O

N CH2 N
N

63

85
85

70

72

66

83

Yield
%

Table 1. Contunied

1785a

1786a
1786a

1779a

1757a

1776a

1770a

IR
(KBr)
(cm−1 )

R

2.3 (3H; s; 5-CH3 ), 2.4 (4H; t; pip. H2 ,
H6 ), 2.8 (4H; t; pip. H3 , H5 ), 3.4 (2H; s;
N-CH2 -C), 4.60 (2H; s; N-CH2 -N-), 6.8-7.4
(8H; m; Arom-H.)
2.2 (3H; s; 5-CH3 ), 2.3 (4H; t; pip. H2 ,
H6 ), 2.7 (4H; t; pip. H3 , H5 ), 3.4 (2H; s;
N-CH2 -C), 4.60 (2H; s; N-CH2 -N-), 5.8
(2H; s; O-CH2 -O), 6.7-7.3 (6H; m; Arom-H.)

2.35 (3H; s; 5-CH3 ), 2.8 (4H; t; pip. H2 ,
H6 ), 3.5 (4H; t; pip. H3 , H5 ), 4.65 (2H; s;
N-CH2 -N-), 6.5-8.2 (7H; m; Arom-H.)

2.35 (3H; s; 5-CH3 ), 2.8 (4H; t; pip. H2 ,
H6 ), 3.2 (4H; t; pip. H3 , H5 ), 4.7 (2H; s;
N-CH2 -N-), 6.8-7.4 (7H; m; Arom-H.)

H-NMR
(CHCl3 -d1 ) δ (ppm)
2.3 (3H; s; 5-CH3 ), 2.4 (3H; s; CO-CH3 ),
2.8 (4H; t; pip. H2 ,H6 ), 3.3 (4H; t; pip.
H3 ,H5 ), 4.65 (2H; s; N-CH2 -N-), 6.8-7.9
(7H; m; Arom-H.)
2.35 (3H; s; 5-CH3 ), 2.8 (4H; t; pip.
H2 ,H6 ), 3.8 (4H; t; pip. H3 ,H5 ), 4.6 (2H; s;
N-CH2 -N-), 6.3-8.3 (6H; m; Arom-H.)
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Analgesic activity of the resulting compounds was investigated by p-benzoquinone-induced writhing
23

test , which is a well-established method of testing the analgesic activity of compounds and suﬃciently
sensitive to detect the eﬀect of analgesics less active than aspirin. Antiinﬂammatory activities of the compounds were assessed by utilizing the carrageenan-induced hind paw edema model24 . Since the carrageenan
edema has been used in the development of indomethacine, many researchers have adapted this procedure for
screening potential anti-inﬂammatory compounds. Carrageenan-induced edema is a nonspeciﬁc inﬂammation maintained by the release of histamine, 5-hydroxytryptamine, kinins and later by prostaglandins25 . The
inhibitory eﬀect of NSAIDs, such as indomethacin, is usually weak in the ﬁrst phase (1-2 h), in contrast with
their strong inhibition in the second phase (3-4 h)26 . Good inhibition of the second phase of carrageenaninduced edema was observed for the compounds tested, suggesting that they interfere with prostaglandin
synthesis (Table 2).
On examination of the results, the derivative 2, which did not carry any substitution on the third
position, was found weaker than that bearing aminoalkyl residue on this position. It could be easily seen
that most of the compounds exhibited antinociceptive activity in the writhing test, and some of them
seemed to be more potent than aspirin under these test conditions. On the other hand, compound 3h did
not show any activity in the writhing test in comparison with the control. Viaud et al. suggested that
the phenylpiperazinyl group enhanced the antinociceptive activity of the 2-oxo-1-aminoalkyl-oxazolo[5,4b]pyridine derivatives synthesized14 . As clearly seen, the oxazolo[5,4-b]pyridine-2-one ring is a bioisoster of
a 2-benzoxazolinone ring system. Therefore, one can conclude that a phenylpiperazinyl moiety on the side
chain may enhance the analgesic activity of these types of compounds. This ﬁnding is in good accordance
with the data reported in our study. It was seen that the introduction of a phenylpiperazinyl group into
the main skeleton (except 3h) caused a noticeable increase in both analgesic and anti-inﬂammatory activity
compared with the starting compound (compare 2/ 3a, 3b, 3c, 3d, 3e, 3i, 3j, 3k), but no signiﬁcant
diﬀerence for the compounds carrying benzyl and 2-pyridyl was observed. The eﬀect of substituents on the
phenyl ring for the analgesic activity was examined. It appeared that the presence of an electron-donating
substituent in the ortho position of the phenyl nucleus (3f, 3h) abolished analgesic properties while electronwithdrawing ones led to increasing activity (3b, 3e). Similarly, an electron-withdrawing substituent in the
meta position (3d) also produced signiﬁcant antinociceptive eﬀects. The best analgesic activity was obtained
for compounds with an electron-withdrawing substituent in the para position of the phenyl nucleus (3a, 3c,
3i). It was also noteworthy that the positions of ﬂuorine and chlorine substitution (2-/4-Cl or 2-/4-F) on
the phenyl group did not induce any remarkable change in the activity of the Mannich derivatives. A less
remarkable but worthy of note result was obtained from the 2-pyrimidinyl substituent on the piperazine
(3j). The compounds bearing acyclic residues as exempliﬁed by structures 2-pyridyl and benzyl showed loss
of activity, thus underscoring the importance of both the size and the shape of the auxiliary unit attached
to the benzoxazolinone template.
Anti-inﬂammatory activity of the synthesized compounds was in parallel with their corresponding
analgesic activities. Compound 3i bearing acetylphenyl moiety was the most potent derivative in this
series. It is well known the compounds with an anti-inﬂammatory eﬀect can exhibit ulcerogenic properties.
Therefore, the ulcerogenic activities of all the compounds were screened. In gastric ulceration studies,
gastrointestinal bleeding was not observed at 100 mg/kg dose level for active compounds. Finally, among the
compounds examined in this study, the compound 3i possessed the most prominent and consistent activity.
Compounds 3a and 3b deserve attention and may be considered for further evaluation. In conclusion, the
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results suggested that the series of 5-methyl-2-benzoxazolinones had a superior analgesic activity proﬁle and
this indicated that these compounds may show activities via a central way.

Table 2. Percent analgesic activity and inhibition of carrageenan paw edema (CPE) of compounds 3a-3n.

Anti-inﬂammatory Activity
Swelling in thickness (x 10−2 mm) ± SEM
(% inhibition)

Comp.
No.
Control
2
3a
3b
3c
3d
3e
3f
3g
3h
3i
3j
3k
3l
3m
3n
INDO
10 mg
ASA
100 mg

90 min

180 min

270 min

360 min

43.7 ± 4.63

52.5 ± 5.09

58.7 ± 5.74

62.8 ± 4.28

36.7 ± 4.2
(19.3)
28.5 ± 3.22
(34.8)
33.8 ± 3.44
(22.7)
36.2 ± 2.55
(17.2)
33.8 ± 3.1
(25.7)
34.8 ± 3.95
(20.4)
37.2 ± 4.19
(14.9)
38.0 ± 5.05
(13.0)
43.2 ± 4.1
(5.1)
29.7 ± 2.5
(34.7)
36.8 ± 3.0
(19.1)
35.2 ± 4.3
(22.6)
35.3 ± 3.9
(22.4)
41.3 ± 3.3
(9.2)
37.5 ± 3.4
(17.6)
30.7 ± 4.2
(29.7)
-

41.3 ± 4.3
(20.1)
36.0 ± 3.13
(31.4)
35.0 ± 4.00
(33.3)
39.8 ± 2.59
(24.2)
35.7 ± 2.3
(30.9)
43.2 ± 4.02
(17.7)
41.3 ± 4.04
(21.3)
41.5 ± 4.91
(20.9)
47.5 ± 3.6
(8.1)
33.0 ± 2.4
(36.2)
37.7 ± 2.2
(27.1)
39.8 ± 3.6
(23.0)
39.2 ± 3.8
(24.2)
45.5 ± 3.6
(11.2)
40.8 ± 3.6
(21.1)
33.0 ± 3.4
(37.1)*
-

46.3 ± 3.9
(19.8)
36.6 ± 3.35
(38.2)
36.7 ± 2.43
(37.5)
44.0 ± 2.52
(25.0)
37.8 ± 2.7
(34.5)*
46.7 ± 3.82
(20.4)
46.5 ± 3.84
(20.8)
45.5 ± 4.85
(22.5)
52.8 ± 3.6
(8.5)
36.3 ± 2.5
(37.1)**
40.0 ± 2.6
(30.7)*
42.0 ± 3.9
(27.2)
43.5 ± 4.0
(24.6)
49.8 ± 3.8
(13.7)
44.8 ± 3.4
(22.3)
35.3 ± 3.3
(39.9)**
-

51.3 ± 4.4
(19.8)
37.7 ± 4.49
(39.9)
38.7 ± 2.63
(38.4)
47.5 ± 3.09
(24.4)
43.7 ± 2.9
(31.7)*
49.8 ± 3.32
(20.7)
49.8 ± 3.52
(20.7)
50.2 ± 4.73
(20.1)
57.2 ± 3.4
(10.6)
40.2 ± 2.9
(37.2)**
41.4 ± 2.3
(35.5)**
44.3 ± 3.7
(30.8)*
46.3 ± 3.2
(27.7)*
54.7 ± 3.6
(14.5)
46.7 ± 3.6
(27.0)
34.2 ± 3.1
(45.5)***
-

* P < 0.05. ** P < 0.01. *** P < 0.001
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Analgesic
Activity
Number of
writhings
± SEM
(% Inhibition)
44.2 ± 1.78

Ratio of
ulceration

32.5 ± 4.2
(29.3)
10.8 ± 1.22
(75.6)
12.2 ± 1.58
(72.4)
18.2 ± 2.21
(58.8)
21.5 ± 2.4
(53.3)*
20.2 ± 2.06
(54.3)
30.2 ± 3.07
(31.7)
25.7 ± 2.40
(41.9)
35.7 ± 4.7
(22.4)
23.2 ± 2.8
(49.6)***
25.7 ± 2.2
(44.1)**
28.5 ± 2.7
(38.0)*
35.3 ± 3.7
(23.2)
37.0 ± 3.2
(19.6)
31.0 ± 2.8
(32.6)*
-

0/6

21.5 ± 2.2
(51.4)***

0/6

0/6
0/6
0/6
0/6
0/6
0/6
2/6**
1/6
0/6
0/6
0/6
0/6
0/6
3/6
0/6
0/6
1/6
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The structure-activity relationships of our series of derivatives (3a-3n) are not fully understood. The
mechanism underlying their analgesic activity remains to some degree unknown. A role of other systems
that implicate dopaminergic, seratonergic or noradrenergic interactions cannot be ruled out. Thus, further
studies are essential to ascertain the mechanisms involved in the analgesic properties of the ring system.
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11. H. Erdoğan, M. Debaert, J.C. Cazin, Arzneim. Forsch./Drug Res. 41, 73-76 (1991).
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